Does Trazodone Make You Constipated? What to Know

Trazodone can cause constipation, though the risk is moderate compared to many other antidepressants. A large network meta-analysis found that people taking trazodone were roughly two and a half times more likely to experience constipation than those on placebo, which places it squarely in the middle of the pack among commonly prescribed antidepressants. The reason it causes constipation at all surprises some clinicians, because trazodone lacks the strong anticholinergic activity that drives constipation in older drugs like amitriptyline. The mechanism turns out to be more interesting than a simple “it blocks this one receptor” story, and the practical risk depends heavily on dose, your baseline gut health, and what else you’re taking.

How Trazodone Stacks Up Against Other Antidepressants

A 2025 network meta-analysis pooled data from trials of 20 different antidepressants to compare their constipation risk head-to-head. Trazodone landed in a cluster of drugs with moderate constipation odds. Its odds ratio compared to placebo was about 2.4, meaning constipation was a bit more than twice as likely in the trazodone groups than in the placebo groups. That’s nearly identical to paroxetine, bupropion, desvenlafaxine, and duloxetine, all of which clustered around that same level of risk.¹

For perspective, the worst offenders for constipation were the tricyclic antidepressants amitriptyline and clomipramine, along with reboxetine, all of which had odds ratios above 4.0. Venlafaxine and mirtazapine also sat noticeably higher than trazodone. On the other end, five drugs showed no significant constipation increase over placebo at all: vortioxetine, fluoxetine, sertraline, citalopram, and escitalopram.¹

So if you’re experiencing constipation on trazodone and wondering whether switching might help, the data give you a reasonable map. SSRIs like fluoxetine and sertraline carry essentially no extra constipation risk. But those drugs come with their own trade-offs, including higher rates of nausea and sexual side effects, so the decision isn’t just about one symptom.

Why Trazodone Causes Constipation Without Being Anticholinergic

The classic explanation for antidepressant-related constipation is anticholinergic activity. Drugs like amitriptyline block acetylcholine receptors throughout the body, and in the gut that slows down the muscular contractions that push food through. Trazodone, however, has minimal anticholinergic activity. Early clinical data from 15 multicenter trials involving hundreds of patients found no statistically significant difference in bowel-related side effects between trazodone and placebo, while the tricyclic antidepressant imipramine was significantly worse.² That finding helped build trazodone’s reputation as gentle on the gut, a reputation that doesn’t quite hold up at the doses used for depression treatment.

The constipation that does occur appears to come from a different set of receptor interactions. Trazodone blocks serotonin 5-HT2A receptors, histamine H1 receptors, and alpha-1 adrenergic receptors.³ Each of these plays a role in how the gut moves things along. Serotonin is a major signaling molecule in the digestive tract, where it helps regulate motility. Blocking 5-HT2 receptors can dampen some of those motility signals. Lab studies have confirmed that trazodone is a potent antagonist at serotonin receptors, which is relevant both for its antidepressant effect and for its downstream influence on gut function.⁴

Histamine H1 blockade adds another layer. Antihistamines are well known to slow gut transit, and trazodone’s sedating properties come partly from this same receptor. The alpha-1 adrenergic blockade, meanwhile, has a less intuitive effect. Alpha-1 receptors help maintain tonic contraction in smooth muscle, including in the internal anal sphincter. A study of the alpha-1 blocker alfuzosin showed that blocking these receptors reduced anal resting pressure by about 30 to 40 percent in women.⁵ That might sound like it would make constipation less likely, and in some clinical contexts alpha-1 blockers are actually used to help with evacuation disorders. But the overall effect of trazodone on the gut involves multiple receptor systems pulling in different directions, and the net result, based on population data, leans toward slowed motility for a meaningful number of people.

How Dose Changes the Picture

Trazodone’s pharmacology shifts substantially depending on how much you take. At the low doses commonly prescribed for insomnia, typically 25 to 100 milligrams, the dominant effects are 5-HT2A antagonism, alpha-1 blockade, and histamine H1 antagonism. These produce sedation without much antidepressant action. At higher doses used for depression, ranging from 150 to 600 milligrams, the drug begins to meaningfully inhibit the serotonin transporter, adding a more traditional antidepressant mechanism on top of the receptor-blocking effects.⁶

This dose-dependent shift matters for constipation risk. At 25 or 50 milligrams for sleep, you’re getting mostly receptor antagonism with minimal serotonin reuptake inhibition. The constipation risk at these doses is lower, though not zero, because H1 and 5-HT2A blockade alone can still slow the gut. At antidepressant doses, you get the added effect of serotonin transporter inhibition layered onto the receptor blockade, which can amplify the gastrointestinal impact. The early multicenter data showing no significant difference from placebo for bowel disturbance were collected at a time when the comparison doses and populations may not have fully captured the higher-dose picture.²

If you’re taking trazodone only for sleep and experiencing new constipation, that’s worth mentioning to your prescriber. There may be room to adjust the dose downward or explore whether another factor, like diet changes or a co-prescribed medication, is the real culprit.

Who Faces the Highest Risk

Constipation from trazodone is a background-level nuisance for most people, but for certain groups it can become a genuine clinical problem. People with Parkinson’s disease are a prime example. Parkinson’s causes widespread autonomic dysfunction, and chronic constipation is already one of the most common non-motor symptoms, affecting the majority of patients. Adding trazodone on top of existing gut dysmotility can make things substantially worse. Expert guidance for treating depression in Parkinson’s specifically flags constipation as a concern with trazodone, noting that medications which further impair bowel motility can degrade quality of life.³

Beyond Parkinson’s, several other situations raise the stakes:

Opioid use: Opioids are among the most potent constipation-causing drugs. If you’re taking an opioid for pain alongside trazodone, the two can compound each other’s gut-slowing effects.
Older age: Gut motility naturally slows with age, and older adults are more likely to be on multiple medications that independently contribute to constipation.
Low fluid and fiber intake: If your diet is already low in fiber or you’re not drinking much water, even a mild drug effect on motility can push you over the threshold into symptomatic constipation.
Other constipating medications: Calcium channel blockers, iron supplements, certain antihistamines, and antacids containing aluminum are all common co-prescriptions that independently slow the gut.

For these groups, the question isn’t whether trazodone alone causes constipation in a vacuum. It’s whether trazodone is the straw that breaks things in a system already predisposed to slowing down.

Dry Mouth, Nausea, and Other Gut-Related Effects

Constipation isn’t the only gastrointestinal side effect of trazodone, and understanding the broader GI profile helps put the constipation risk in context. Trazodone has a notably nausea-neutral profile. Unlike SSRIs, which often cause nausea during the first weeks of treatment, trazodone shows no significant increase in nausea compared to placebo. This is likely because its 5-HT2A antagonism and antihistamine activity counteract the nausea-promoting effects that serotonin reuptake inhibition would otherwise produce.⁷

Dry mouth, on the other hand, is surprisingly common with trazodone. This is unexpected given the drug’s minimal anticholinergic activity, since dry mouth is traditionally considered an anticholinergic side effect. The leading explanation is that trazodone’s alpha-1 adrenergic blockade reduces parasympathetic outflow to the salivary glands, producing dryness through a different pathway than the classic anticholinergic mechanism.⁷ Dry mouth matters for digestive comfort too. Saliva plays a real role in the early stages of digestion, and chronic mouth dryness can make eating less pleasant and reduce the lubrication of food before it enters the stomach.

Sedation, dizziness, and fatigue are also commonly reported, and these can indirectly affect bowel habits by making people less physically active. Reduced movement throughout the day is one of the most reliable contributors to sluggish digestion.

Practical Steps if Trazodone Is Slowing You Down

If you’ve started trazodone and notice a change in your bowel habits, the first step is not to stop the medication abruptly. Constipation from trazodone tends to be mild to moderate for most people and is often manageable with straightforward adjustments. Increasing water intake and dietary fiber is the most evidence-supported first-line approach for any medication-related constipation. Soluble fiber from sources like oats, beans, and psyllium tends to be better tolerated than insoluble fiber from wheat bran, which can cause bloating in some people.

Regular physical activity, even a daily walk, helps stimulate colonic motility. If those steps aren’t enough, over-the-counter osmotic laxatives like polyethylene glycol are generally safe for ongoing use and work by drawing water into the colon. Stimulant laxatives like senna can help in the short term but aren’t ideal for daily use over long periods.

Timing can also matter. Some people find that taking trazodone with a meal rather than on an empty stomach reduces GI side effects, though the main reason trazodone is taken at bedtime is for its sedating properties. If constipation is persistent and bothersome enough to affect your quality of life, that’s a conversation to have with your prescriber. Given the range of antidepressant options available, and the fact that several SSRIs show no meaningful constipation risk at all, there may be alternatives worth trying depending on what the trazodone is treating.

The Reputation Versus the Data

Trazodone’s early clinical reputation was built partly on the contrast with tricyclic antidepressants. Compared to imipramine and amitriptyline, it genuinely is far gentler on the gut. Those early multicenter comparisons showed that trazodone’s anticholinergic side effect profile was statistically indistinguishable from placebo, which was a real advantage in the 1980s when tricyclics were the standard of care.² That finding got generalized over the years into a broader assumption that trazodone doesn’t cause constipation at all. The more recent meta-analytic data tells a more nuanced story: trazodone does carry a real, statistically significant constipation risk compared to placebo, but it’s far from the worst option.¹

The disconnect between “minimal anticholinergic activity” and “still causes constipation” is a useful reminder that the gut doesn’t care which textbook category a drug falls into. Serotonin receptors, histamine receptors, and adrenergic receptors all play roles in digestive motility, and a drug that touches several of them simultaneously can slow things down through routes that have nothing to do with acetylcholine. Trazodone’s constipation effect is real but modest, and for many people it’s a tolerable trade-off given the drug’s other advantages, especially its lack of nausea and its usefulness as a sleep aid.

Extended-Release Formulations

Trazodone is available in both immediate-release and extended-release formulations. The extended-release version, marketed as Oleptro, was designed to allow once-daily dosing and smoother drug levels over time. In theory, a more gradual release of the drug could reduce peak-related side effects like dizziness and sedation, and might also spread out the GI impact rather than hitting the gut with a concentrated dose all at once. In practice, the extended-release formulation is primarily used at antidepressant doses rather than the low sleep-aid doses where immediate-release trazodone dominates. If you’re prescribed the extended-release version, you’re likely taking a dose in the range where constipation risk is more relevant, so it’s still worth keeping an eye on your gut function and mentioning any changes to your doctor.

One thing to note: extended-release tablets should not be crushed or split, as this destroys the controlled-release mechanism and dumps the full dose at once. If you need a lower dose, the immediate-release formulation is the appropriate choice and is easily cut with a pill splitter.

1
PubMed Central. Comparative gastrointestinal effects of antidepressants for the acute treatment of adults with major depressive disorder: a network and dose‒response meta-analysis
2
PubMed. Lack of anticholinergic side effects with a new antidepressent–trazodone
3
PubMed Central. Trazodone for management of depression in Parkinson’s disease: expert opinion and proposal for a treatment algorithm
4
PubMed Central. Interactions of trazodone with serotonin neurons and receptors
5
PubMed Central. Effects of Alfuzosin, an Alpha-1 Adrenergic Antagonist on Anal Pressures and Bowel Habits, in Women With and Without Defecatory Disorders
6
Psychopharmacology Institute. Trazodone Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
7
Psychopharmacology Institute. Gastrointestinal Side Effects of Antidepressants: Mechanisms, Comparison and Management Strategies